The Filings Report

BioMarin Pharmaceuticals Inc

BMRNNasdaqCIK 1048477Healthcare / Drug Manufacturersfiscal year ends December70 quarters since 2009

Revenue, Q3 FY2026
$1.0B
+32.0% on Q3 FY2025
Net income
−$123M
−299.5% on Q3 FY2025
Free cash flow
$160M
−53.0% on Q3 FY2025
Diluted EPS
$-0.63
−293.7% on Q3 FY2025
Revenue, TTM
$3.7B
trailing four quarters
Net margin, TTM
-0.5%
net income −$19M
Free cash flow, TTM
$558M
$677M less $119M capex
Cash and equivalents
$736M
long-term debt $3.5B, Sep 30, 2026
Shares, 12-month change
+0.8%
194M shares, Sep 30, 2026
Buybacks, TTM
—
no yield
Dividends, TTM
—
no yield
Market value
$10.9B
at the close, buybacks

Latest quarter Q3 FY2026, filed November 3, 2026. Trailing figures sum the latest four quarters. Market values at the latest close, from a market data vendor.

In Q3 FY2026, the quarter ended September 30, 2026, BioMarin Pharmaceuticals Inc reported revenue of $1.0B, +32.0% on Q3 FY2025, and net loss of $123M (−299.5%). Operating margin was −8.0%. Free cash flow, operating cash flow less capital expenditures, was $160M ($188M less $28M). Diluted earnings per share were $-0.63.

Share price

Daily candlesticks from November 11, 2024 to November 9, 2026, with each earnings release marked; a release after the close marks the day it came out, so its reaction is the next candle. See this earnings season for every company’s reaction.

BMRN daily priceSplit-adjusted, US dollars; an earnings release
Nov 9, 2026O $56.56 · H $57.45 · L $54.71 · C $57.18 · +2.05% on the dayOver the range: +11.12%, Nov 10, 2025 to Nov 9, 2026
$48$54$60$66$72Nov 25Jan 26Apr 26Jun 26Aug 26Nov 26

The last 16 quarters

Q4 FY2022 to Q3 FY2026, through the filing of November 3, 2026.

Revenue and net incomeRevenueNet income
−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $538MQ4'22, Net income: −$249KQ4'22Q1'23, Revenue: $596MQ1'23, Net income: $51MQ1'23Q2'23, Revenue: $595MQ2'23, Net income: $56MQ2'23Q3'23, Revenue: $581MQ3'23, Net income: $40MQ3'23Q4'23, Revenue: $646MQ4'23, Net income: $20MQ4'23Q1'24, Revenue: $649MQ1'24, Net income: $89MQ1'24Q2'24, Revenue: $712MQ2'24, Net income: $107MQ2'24Q3'24, Revenue: $746MQ3'24, Net income: $106MQ3'24Q4'24, Revenue: $747MQ4'24, Net income: $125MQ4'24Q1'25, Revenue: $745MQ1'25, Net income: $186MQ1'25Q2'25, Revenue: $825MQ2'25, Net income: $241MQ2'25Q3'25, Revenue: $776MQ3'25, Net income: −$31MQ3'25Q4'25, Revenue: $875MQ4'25, Net income: −$47MQ4'25Q1'26, Revenue: $766MQ1'26, Net income: $106MQ1'26Q2'26, Revenue: $990MQ2'26, Net income: $45MQ2'26Q3'26, Revenue: $1.0BQ3'26, Net income: −$123MQ3'26−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $538MQ4'22, Net income: −$249KQ4'22Q1'23, Revenue: $596MQ1'23, Net income: $51MQ1'23Q2'23, Revenue: $595MQ2'23, Net income: $56MQ2'23Q3'23, Revenue: $581MQ3'23, Net income: $40MQ3'23Q4'23, Revenue: $646MQ4'23, Net income: $20MQ4'23Q1'24, Revenue: $649MQ1'24, Net income: $89MQ1'24Q2'24, Revenue: $712MQ2'24, Net income: $107MQ2'24Q3'24, Revenue: $746MQ3'24, Net income: $106MQ3'24Q4'24, Revenue: $747MQ4'24, Net income: $125MQ4'24Q1'25, Revenue: $745MQ1'25, Net income: $186MQ1'25Q2'25, Revenue: $825MQ2'25, Net income: $241MQ2'25Q3'25, Revenue: $776MQ3'25, Net income: −$31MQ3'25Q4'25, Revenue: $875MQ4'25, Net income: −$47MQ4'25Q1'26, Revenue: $766MQ1'26, Net income: $106MQ1'26Q2'26, Revenue: $990MQ2'26, Net income: $45MQ2'26Q3'26, Revenue: $1.0BQ3'26, Net income: −$123MQ3'26−$500M$0$500M$1.0B$1.5BQ4'22, Revenue: $538MQ4'22, Net income: −$249KQ1'23, Revenue: $596MQ1'23, Net income: $51MQ1'23Q2'23, Revenue: $595MQ2'23, Net income: $56MQ3'23, Revenue: $581MQ3'23, Net income: $40MQ3'23Q4'23, Revenue: $646MQ4'23, Net income: $20MQ1'24, Revenue: $649MQ1'24, Net income: $89MQ1'24Q2'24, Revenue: $712MQ2'24, Net income: $107MQ3'24, Revenue: $746MQ3'24, Net income: $106MQ3'24Q4'24, Revenue: $747MQ4'24, Net income: $125MQ1'25, Revenue: $745MQ1'25, Net income: $186MQ1'25Q2'25, Revenue: $825MQ2'25, Net income: $241MQ3'25, Revenue: $776MQ3'25, Net income: −$31MQ3'25Q4'25, Revenue: $875MQ4'25, Net income: −$47MQ1'26, Revenue: $766MQ1'26, Net income: $106MQ1'26Q2'26, Revenue: $990MQ2'26, Net income: $45MQ3'26, Revenue: $1.0BQ3'26, Net income: −$123MQ3'26

Net income losses drawn in red.

Free cash flow
−$200M$0$200M$400MQ4'22, Free cash flow: −$29MQ4'22Q1'23, Free cash flow: −$98MQ1'23Q2'23, Free cash flow: $48MQ2'23Q3'23, Free cash flow: $114MQ3'23Q4'23, Free cash flow: −$1MQ4'23Q1'24, Free cash flow: $21MQ1'24Q2'24, Free cash flow: $97MQ2'24Q3'24, Free cash flow: $203MQ3'24Q4'24, Free cash flow: $166MQ4'24Q1'25, Free cash flow: $158MQ1'25Q2'25, Free cash flow: $168MQ2'25Q3'25, Free cash flow: $340MQ3'25Q4'25, Free cash flow: $59MQ4'25Q1'26, Free cash flow: $200MQ1'26Q2'26, Free cash flow: $139MQ2'26Q3'26, Free cash flow: $160MQ3'26−$200M$0$200M$400MQ4'22, Free cash flow: −$29MQ4'22Q1'23, Free cash flow: −$98MQ1'23Q2'23, Free cash flow: $48MQ2'23Q3'23, Free cash flow: $114MQ3'23Q4'23, Free cash flow: −$1MQ4'23Q1'24, Free cash flow: $21MQ1'24Q2'24, Free cash flow: $97MQ2'24Q3'24, Free cash flow: $203MQ3'24Q4'24, Free cash flow: $166MQ4'24Q1'25, Free cash flow: $158MQ1'25Q2'25, Free cash flow: $168MQ2'25Q3'25, Free cash flow: $340MQ3'25Q4'25, Free cash flow: $59MQ4'25Q1'26, Free cash flow: $200MQ1'26Q2'26, Free cash flow: $139MQ2'26Q3'26, Free cash flow: $160MQ3'26−$200M$0$200M$400MQ4'22, Free cash flow: −$29MQ1'23, Free cash flow: −$98MQ1'23Q2'23, Free cash flow: $48MQ3'23, Free cash flow: $114MQ3'23Q4'23, Free cash flow: −$1MQ1'24, Free cash flow: $21MQ1'24Q2'24, Free cash flow: $97MQ3'24, Free cash flow: $203MQ3'24Q4'24, Free cash flow: $166MQ1'25, Free cash flow: $158MQ1'25Q2'25, Free cash flow: $168MQ3'25, Free cash flow: $340MQ3'25Q4'25, Free cash flow: $59MQ1'26, Free cash flow: $200MQ1'26Q2'26, Free cash flow: $139MQ3'26, Free cash flow: $160MQ3'26

Operating cash flow less capital expenditures; negative quarters in red.

Cash and equivalents against long-term debtCash and equivalentsLong-term debt
$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $725MQ4'22Q1'23, Cash and equivalents: $580MQ1'23Q2'23, Cash and equivalents: $694MQ2'23Q3'23, Cash and equivalents: $785MQ3'23Q4'23, Cash and equivalents: $755MQ4'23Q1'24, Cash and equivalents: $747MQ1'24Q2'24, Cash and equivalents: $972MQ2'24Q3'24, Cash and equivalents: $675MQ3'24Q4'24, Cash and equivalents: $943MQ4'24Q1'25, Cash and equivalents: $1.0BQ1'25Q2'25, Cash and equivalents: $1.2BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25Q4'25, Cash and equivalents: $1.3BQ4'25, Long-term debt: $597MQ4'25Q1'26, Cash and equivalents: $2.2BQ1'26, Long-term debt: $1.4BQ1'26Q2'26, Cash and equivalents: $874MQ2'26, Long-term debt: $3.5BQ2'26Q3'26, Cash and equivalents: $736MQ3'26, Long-term debt: $3.5BQ3'26$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $725MQ4'22Q1'23, Cash and equivalents: $580MQ1'23Q2'23, Cash and equivalents: $694MQ2'23Q3'23, Cash and equivalents: $785MQ3'23Q4'23, Cash and equivalents: $755MQ4'23Q1'24, Cash and equivalents: $747MQ1'24Q2'24, Cash and equivalents: $972MQ2'24Q3'24, Cash and equivalents: $675MQ3'24Q4'24, Cash and equivalents: $943MQ4'24Q1'25, Cash and equivalents: $1.0BQ1'25Q2'25, Cash and equivalents: $1.2BQ2'25Q3'25, Cash and equivalents: $1.3BQ3'25Q4'25, Cash and equivalents: $1.3BQ4'25, Long-term debt: $597MQ4'25Q1'26, Cash and equivalents: $2.2BQ1'26, Long-term debt: $1.4BQ1'26Q2'26, Cash and equivalents: $874MQ2'26, Long-term debt: $3.5BQ2'26Q3'26, Cash and equivalents: $736MQ3'26, Long-term debt: $3.5BQ3'26$0$1B$2B$3B$4BQ4'22, Cash and equivalents: $725MQ1'23, Cash and equivalents: $580MQ1'23Q2'23, Cash and equivalents: $694MQ3'23, Cash and equivalents: $785MQ3'23Q4'23, Cash and equivalents: $755MQ1'24, Cash and equivalents: $747MQ1'24Q2'24, Cash and equivalents: $972MQ3'24, Cash and equivalents: $675MQ3'24Q4'24, Cash and equivalents: $943MQ1'25, Cash and equivalents: $1.0BQ1'25Q2'25, Cash and equivalents: $1.2BQ3'25, Cash and equivalents: $1.3BQ3'25Q4'25, Cash and equivalents: $1.3BQ4'25, Long-term debt: $597MQ1'26, Cash and equivalents: $2.2BQ1'26, Long-term debt: $1.4BQ1'26Q2'26, Cash and equivalents: $874MQ2'26, Long-term debt: $3.5BQ3'26, Cash and equivalents: $736MQ3'26, Long-term debt: $3.5BQ3'26

Positions at each quarter end, as filed; short-term investments are not included.

Income statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

BioMarin Pharmaceuticals Inc income statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 24, 2025YoYQ3 FY2026vs Q3 FY2025
Revenue1,025990766875776825745747+32.0%
Cost of revenue205203195276140150152136+46.6%
Gross profit—————————
Research and development—207179192409161159174—
Selling, general and administrative334396258446268232206267+24.3%
Operating income(82)111130(45)(47)277224161−75.8%
Other income (expense)—————————
Pretax income(132)61141(27)(26)298238170−400.6%
Income tax(9)1736194575245−302.2%
Net income(123)45106(47)(31)241186125−299.5%
Diluted EPS ($)(0.63)0.230.54—(0.16)1.230.95—−293.7%
Diluted shares (millions)194194198—192197196——

Fourth quarters are the fiscal year less the first nine months when the filer reports no discrete fourth quarter, and are marked. Diluted EPS is never derived, so a derived quarter shows none. Italic figures are derived.

Balance sheet

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

BioMarin Pharmaceuticals Inc balance sheet, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 24, 2025YoYQ3 FY2026vs Q3 FY2025
Cash and equivalents7368742,2221,3121,2501,2141,049943−41.1%
Short-term investments000249228218224195−100.0%
Total current assets3,9213,9724,6053,9533,8553,8053,4683,232+1.7%
Total assets11,56911,7238,5917,5947,6157,4567,1476,989+51.9%
Total current liabilities1,6051,664793759798684628607+101.0%
Long-term debt3,5153,5281,430597—————
Total liabilities5,3135,4022,3791,5071,5581,4291,3541,331+241.0%
Stockholders’ equity6,2566,3226,2126,0876,0576,0275,7935,658+3.3%
Shares outstanding (millions)194194193192192192192191—

Positions at each period end. Nothing on this statement is derived. Long-term debt is the filed noncurrent line only; no total-debt composite is constructed across filers. Italic figures are derived.

Cash flow statement

Last eight quarters, newest first, through Q3 FY2026 filed November 3, 2026.

BioMarin Pharmaceuticals Inc cash flow statement, quarterly
Millions of dollarsQ3 FY2026ended Sep 30, 2026filed Nov 3, 2026Q2 FY2026ended Jun 30, 2026filed Aug 6, 2026Q1 FY2026ended Mar 31, 2026filed May 5, 2026Q4 FY2025ended Dec 31, 2025filed Feb 26, 2026Q3 FY2025ended Sep 30, 2025filed Oct 28, 2025Q2 FY2025ended Jun 30, 2025filed Aug 5, 2025Q1 FY2025ended Mar 31, 2025filed May 2, 2025Q4 FY2024ended Dec 31, 2024filed Feb 24, 2025YoYQ3 FY2026vs Q3 FY2025
Operating cash flow188168221100369185174186−48.9%
Capital expenditures2829214128171720−0.5%
Free cash flow (CFO − capex)16013920059340168158166−53.0%
Depreciation and amortization13098162018192224+605.7%
Share repurchases—————————
Dividends paid—————————

10-Qs file cash flows as year-to-date totals, so quarterly figures are differenced from consecutive filings and marked. Free cash flow is operating cash flow less capital expenditures, computed from the two filed lines. Italic figures are derived.

Annual statements

Every fiscal year filed, newest first, through FY2025 filed February 26, 2026.

Income statement

BioMarin Pharmaceuticals Inc income statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 24, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Aug 4, 2010FY2008ended Dec 31, 2008filed Aug 4, 2010
Revenue3,2212,8542,4192,0961,8461,8601,7041,4911,3141,117890749548501441376325296
Cost of revenue717580532503471524359315242210152122889284706653
Gross profit——————————————————
Research and development92274774765062962871569661166263546235530221414711593
Selling, general and administrative1,1531,009892823759738681604554477402302235198175152124107
Operating income409484186161(82)(43)(100)(124)(15)(803)(111)(93)(156)(110)(34)11640
Other income (expense)——————————————————
Pretax income482542189150(75)(49)(95)(143)(36)(831)(155)(125)(177)(118)(44)(21)133
Income tax134115218(11)(903)(71)(65)81(201)1790(4)10(227)13
Net income349427168142(64)854(24)(77)(117)(630)(172)(134)(176)(114)(54)206031
Diluted EPS ($)1.802.210.870.75(0.35)4.50(0.13)(0.44)(0.67)(3.81)(1.07)(0.92)—(0.95)(0.48)1.730.000.29
Diluted shares (millions)197197192189183192179177174166160146—120112126100104

Balance sheet

BioMarin Pharmaceuticals Inc balance sheet, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 24, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Aug 4, 2010FY2008ended Dec 31, 2008filed Aug 4, 2010
Cash and equivalents1,3129437557255876494374945984083978755691814688167223
Short-term investments24919531956742741631659079838119670216267149186134—
Total current assets3,9533,2322,9562,7512,2742,3421,9422,0562,2071,4221,0901,3981,137743470504468—
Total assets7,5946,9896,8426,3756,0055,8484,6904,4274,6334,0243,7292,4752,2441,5681,3061,263917—
Total current liabilities7596071,177589546493933523817439445236183170948478—
Long-term debt597—————————————————
Total liabilities1,5071,3311,8901,7721,7391,7421,5681,4591,8241,2571,329947903553533545595—
Stockholders’ equity6,0875,6584,9524,6034,2664,1013,1222,9682,8092,7662,4011,5281,3411,016773717322277
Shares outstanding (millions)192191189187184182180178176173162159144126115111——

Cash flow statement

BioMarin Pharmaceuticals Inc cash flow statement, annual
Millions of dollarsFY2025ended Dec 31, 2025filed Feb 26, 2026FY2024ended Dec 31, 2024filed Feb 24, 2025FY2023ended Dec 31, 2023filed Feb 26, 2024FY2022ended Dec 31, 2022filed Feb 27, 2023FY2021ended Dec 31, 2021filed Feb 25, 2022FY2020ended Dec 31, 2020filed Feb 26, 2021FY2019ended Dec 31, 2019filed Feb 27, 2020FY2018ended Dec 31, 2018filed Feb 28, 2019FY2017ended Dec 31, 2017filed Feb 26, 2018FY2016ended Dec 31, 2016filed Feb 27, 2017FY2015ended Dec 31, 2015filed Feb 29, 2016FY2014ended Dec 31, 2014filed Mar 2, 2015FY2013ended Dec 31, 2013filed Feb 26, 2014FY2012ended Dec 31, 2012filed Feb 26, 2013FY2011ended Dec 31, 2011filed Feb 22, 2012FY2010ended Dec 31, 2010filed Feb 24, 2011FY2009ended Dec 31, 2009filed Aug 4, 2010FY2008ended Dec 31, 2008filed Aug 4, 2010
Operating cash flow828573159176305854820(9)(228)——(60)18181988(9)
Capital expenditures103859712196114145145199148228117654573499056
Free cash flow (CFO − capex)7254876355209(29)(97)(124)(208)(376)——(125)(27)(55)(31)(2)(66)
Depreciation and amortization80961041021081051059688974746364435282118
Share repurchases———005000——————————
Dividends paid——————————————————

Insider activity

Form 4 filings by officers, directors and 10% owners, November 9, 2024 to November 9, 2026. Only open-market purchases and sales count as buys and sells; awards, exercises, tax withholding and gifts are listed in grey and never counted.

Bought, three months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, three months
$1M
1 sales by 1 insider; officers and directors $1M
Bought, twelve months
$0
0 purchases by 0 insiders; officers and directors $0
Sold, twelve months
$4M
5 sales by 3 insiders; officers and directors $4M

The last 25 transactions

TradedInsiderRoleTransactionSharesPriceValueHeld afterFiled
Sep 30, 2026Friberg Gregory REVP, Chief R&D Officertax withholding4,086$60.00$245K47,732Oct 1, 2026
Sep 10, 2026Plenge Robert MDirectoraward6,140$0.00—6,140Sep 14, 2026
Sep 2, 2026Davis George EricEVP, Chief Legal Officeropen-market sale17,557$66.28$1M61,003Sep 3, 2026
Jun 2, 2026Countouriotis AthenaDirectoraward7,490$0.00—21,040Jun 4, 2026
Jun 2, 2026Walbert Timothy PDirectoraward7,490$0.00—17,270Jun 4, 2026
Jun 2, 2026Ho MaykinDirectoraward7,490$0.00—35,500Jun 4, 2026
Jun 2, 2026Hombach Robert J.Directoraward7,490$0.00—49,360Jun 4, 2026
Jun 2, 2026Enyedy Mark JDirectoraward7,490$0.00—21,040Jun 4, 2026
Jun 2, 2026Dere Willard HDirectoraward7,490$0.00—46,440Jun 4, 2026
Jun 2, 2026Clark Ian TDirectoraward7,490$0.00—14,490Jun 4, 2026
Jun 2, 2026Bodem Barbara W.Directoraward7,490$0.00—21,045Jun 4, 2026
Jun 2, 2026Anderson Elizabeth MDirectoraward7,490$0.00—41,940Jun 4, 2026
May 20, 2026Hubbard CristinEVP, Chief Commercial Officertax withholding2,318$50.20$116K42,472May 21, 2026
May 7, 2026Friberg Gregory REVP, Chief R&D Officeropen-market sale3,281$53.85$177K51,818May 11, 2026
Mar 18, 2026Davis George EricEVP, Chief Legal Officertax withholding1,273$56.05$71K78,560Mar 19, 2026
Mar 17, 2026Guyer Charles GregEVP, Chief Technical Officertax withholding1,693$56.05$95K84,140Mar 19, 2026
Mar 17, 2026Mueller BrianEVP, Chief Financial Officertax withholding2,117$56.05$119K123,314Mar 19, 2026
Mar 17, 2026Hardy AlexanderChief Executive Officer, Directortax withholding4,252$56.05$238K214,635Mar 19, 2026
Mar 17, 2026Hubbard CristinEVP, Chief Commercial Officertax withholding1,245$56.05$70K44,790Mar 18, 2026
Mar 17, 2026Friberg Gregory REVP, Chief R&D Officertax withholding1,629$56.05$91K55,099Mar 18, 2026
Mar 16, 2026Hubbard CristinEVP, Chief Commercial Officeraward15,410$0.00—46,035Mar 18, 2026
Mar 16, 2026Friberg Gregory REVP, Chief R&D Officeraward19,150$0.00—56,728Mar 18, 2026
Mar 16, 2026Guyer Charles GregEVP, Chief Technical Officeraward14,990$0.00—85,833Mar 17, 2026
Mar 16, 2026Davis George EricEVP, Chief Legal Officeraward14,570$0.00—79,833Mar 17, 2026
Mar 16, 2026Davis George EricEVP, Chief Legal Officertax withholding7,177$58.51$420K65,263Mar 17, 2026

Full insider history for BioMarin Pharmaceuticals Inc, or insider activity across all companies. A record of filings, not a recommendation.

Sources

Fiscal year ends in month 12; periods are labeled with the issuer's own fiscal calendar. Values are as most recently filed (restatements apply; per-share values are on current split basis per the connector's split table, flagged in adjusted). Flow items flagged in `derived` were computed (Q4 = FY − nine months; quarterly cash flow differenced from year-to-date filings) rather than read from a filing. `reconciliation.repaired` lists periods where a full-year figure was filed in a quarter slot: that row was dropped and the quarter rebuilt from the annual figure. `reconciliation.quarantined` lists periods where four filed quarters do not sum to the filed year — those quarterly values are withheld, so a blank there is a withholding rather than an absence of reporting.

Filer
BioMarin Pharmaceutical Inc, CIK 1048477 on EDGAR
Extract generated
November 8, 2026
Withheld
2 line-years whose four quarters do not sum to the filed year: rnd FY2009, capex FY2014
Repaired
4 quarters where a full-year figure was filed in a quarter slot and the quarter was rebuilt: income tax FY2012, operating income FY2017, pretax income FY2017, income tax FY2022
XBRL concepts behind each line

Income statement

Revenue: RevenueFromContractWithCustomerExcludingAssessedTax, Revenues
Cost of revenue: CostOfRevenue
Gross profit: not filed
Research and development: ResearchAndDevelopmentExpense
Selling, general and administrative: SellingGeneralAndAdministrativeExpense
Operating income: OperatingIncomeLoss
Other income (expense): not filed
Pretax income: IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest, IncomeLossFromContinuingOperationsBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments
Income tax: IncomeTaxExpenseBenefit
Net income: NetIncomeLoss
Diluted EPS ($): EarningsPerShareDiluted
Diluted shares (millions): WeightedAverageNumberOfDilutedSharesOutstanding

Balance sheet

Cash and equivalents: CashAndCashEquivalentsAtCarryingValue
Short-term investments: AvailableForSaleSecuritiesDebtSecuritiesCurrent, ShortTermInvestments
Total current assets: AssetsCurrent
Total assets: Assets
Total current liabilities: LiabilitiesCurrent
Long-term debt: LongTermDebt, LongTermDebtNoncurrent
Total liabilities: Liabilities
Stockholders’ equity: StockholdersEquity
Shares outstanding (millions): dei:EntityCommonStockSharesOutstanding

Cash flow statement

Operating cash flow: NetCashProvidedByUsedInOperatingActivities
Capital expenditures: PaymentsToAcquirePropertyPlantAndEquipment
Free cash flow (CFO − capex): not filed
Depreciation and amortization: DepreciationAndAmortization, DepreciationDepletionAndAmortization
Share repurchases: PaymentsForRepurchaseOfCommonStock
Dividends paid: not filed

The data

The statements on this page as files, generated November 8, 2026.

JSON file
/data/financials/BMRN.json